News

Zacks.com on MSN1d
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...
Medscape5d
Why Are RSV Vaccine Rates so Shockingly Low?
Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...
Physician's Weekly3d
Understanding Parental Views on RSV and Childhood Vaccines
Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...
pharmaphorum4d
Mpox shows need for new approaches to therapeutic antibody research
A successful example of these technologies coming together is Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip), an anti-RSV monoclonal antibody approved for the prevention of RSV in infants.
Deutsche Bank Sticks to Its Hold Rating for Sanofi (SNYNF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi, with a price target of €100.00. The company’s shares closed yesterday at $95.42. Take advantage of ...